SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Kreuzberger N., Hirsch C., Chai KL., Piechotta V., Valk SJ., Estcourt LJ., Salomon S., Tomlinson E., Monsef I., Wood EM., So-Osman C., Roberts DJ., McQuilten Z., Skoetz N.
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.